I know Dr Jay mentioned CCR5 deletion in a intervi

I know Dr Jay mentioned CCR5 deletion in a interview and how some individuals express CCR5 well others do not.

I’m sure ohm will have a better answer. Would this have any impact on how Leronlimab reacts with certain people depending on how well they do or don’t express CCR5 receptors?

“Some hypotheses have been drawn to explain the evolution and the selective advantage conferred by CCR5 delta-32 allele in humans, such as an increased resistance to plague or smallpox, but none is presently conclusive.[41]

It’s a pretty good read.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185609/

Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™

Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )

Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)

Contact FireGate Biotech

Principal Investigator:
FG001|FG002|FG003

https://zenodo.org/records/17290045?token=eyJ...UkeT_EvKIQ


https://firegatebiotech.com/2025

https://zenodo.org/records/17291133?token=eyJ...kN7msthgMA





— Jeremiah 51:36